New drug cocktail targets advanced cervical cancer after other treatments fail
NCT ID NCT07363330
First seen Feb 01, 2026 · Last updated May 20, 2026 · Updated 11 times
Summary
This study tests a combination of two drugs, Utidelone and Toripalimab, in people with recurrent or metastatic cervical cancer whose cancer has worsened after standard chemotherapy. The goal is to see if this treatment can shrink tumors and control the disease. About 32 participants will receive the drugs intravenously in 21-day cycles, and their tumors will be checked every 6 weeks. This is not a cure, but aims to manage the cancer and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.